KPV
Lys-Pro-Val tripeptide / α-MSH fragment
Tripeptide fragment of alpha-MSH with potent gut anti-inflammatory effects. One of the few peptides with genuine oral bioavailability making it uniquely valuable for gut-specific research.
Mechanism of action
Inhibits NF-kB signaling the master inflammatory pathway. Blocks TNF-alpha IL-6 and IL-8 production. Three amino acid size allows oral bioavailability — survives stomach acid for gut-targeted applications. Works both systemically and locally in gut tissue.
Effects in the body
KPV solves the oral bioavailability problem that makes most peptides injection-dependent. Its tiny three amino acid size means it survives digestion making it uniquely valuable for gut-specific inflammatory research. IBD Crohns and leaky gut are the primary research applications.
Pros & cons (from the literature)
- Oral bioavailability — genuinely rare for therapeutic peptides
- Gut targeted anti-inflammatory without broad immunosuppression
- Strong IBD and Crohns preclinical data
- Well tolerated in animal studies
- Can be combined with BPC-157 orally for gut protocols
- Limited human clinical trial data
- Dosing in humans not established
- Regulatory pathway unclear for oral drug use
- Relatively new to clinical research protocols
Protocol summary (from published research)
Dosing ranges reproduced from published research literature. Not a prescription, not medical advice.
FDA & regulatory status
Evidence base
Preclinical IBD data compelling. Phase I and II human safety data emerging. No Phase III. Mechanistically well characterized with clear NF-kB inhibition data.
Primary research sources
Peer-reviewed literature referenced throughout this profile is drawn from PubMed, Cell Metabolism, and clinical trial registries cited in the evidence base above.